Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1996 3
1997 1
1998 3
2000 1
2001 3
2002 4
2003 4
2004 4
2005 3
2006 9
2007 8
2008 9
2009 8
2010 5
2012 1
2013 9
2014 2
2015 3
2016 2
2017 3
2018 5
2019 3
2020 2
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Ridker PM, et al. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. N Engl J Med. 2008. PMID: 18997196 Free article. Clinical Trial.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.
Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie. Boily G, et al. Among authors: goulet s. HPB (Oxford). 2015 Jan;17(1):52-65. doi: 10.1111/hpb.12273. Epub 2014 Jun 24. HPB (Oxford). 2015. PMID: 24961288 Free PMC article. Review.
Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO).
Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouëlian V, Letarte N; Comité de l'évolution des pratiques en oncologie; Comité de l'évolution des pratiques en oncologie; Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lespérance B, Letarte N, Morneau M, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sidéris L, Vincent F. Morneau M, et al. Among authors: goulet s. Gynecol Oncol. 2013 Oct;131(1):231-40. doi: 10.1016/j.ygyno.2013.07.084. Epub 2013 Jul 19. Gynecol Oncol. 2013. PMID: 23872191 Review.
86 results